Literature DB >> 21389751

Medulloblastoma with extensive nodularity undergoing post-therapeutic maturation to a gangliocytoma: a case report and literature review.

Daniel Chelliah1, Christian Mensah Sarfo-Poku, Baldassarre D Stea, Jennifer Gardetto, Jonathan Zumwalt.   

Abstract

We present a report of a 12-year-old boy diagnosed with medulloblastoma at 22 months of age. A gross total resection was performed followed by adjuvant systemic chemotherapy due to his young age; however, the tumor recurred locally in the posterior fossa 7 months later. The recurrent tumor was excised and he received craniospinal radiation with a boost given to the posterior fossa followed by high-dose chemotherapy. He remained disease free for approximately 10 years without major neurologic deficit and only mild cognitive impairment. A routine follow-up MRI of the brain revealed an enhancing mass. The patient underwent surgical debulking and pathological examination revealed no residual immature medulloblastoma cells but instead mature ganglion cells, consistent with a gangliocytoma. The apparent maturation of primitive medulloblastoma cells is a rare phenomenon, which may have ensued from the long-term effects of adjuvant therapies inducing advanced cellular maturation.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21389751     DOI: 10.1159/000322896

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  2 in total

1.  Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy.

Authors:  Manila Antonelli; Andrey Korshunov; Angela Mastronuzzi; Francesca Diomedi Camassei; Andrea Carai; Giovanna S Colafati; Stefan M Pfister; Marcel Kool; Felice Giangaspero
Journal:  Virchows Arch       Date:  2015-02-20       Impact factor: 4.064

Review 2.  Post-treatment maturation of medulloblastoma in children: two cases and a literature review.

Authors:  Xuanxuan Wu; Yudong Zhou; Lusheng Li; Ping Liang; Xuan Zhai
Journal:  J Int Med Res       Date:  2018-10-01       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.